Related to Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial in RCC

• Maxygen and Astellas Create JV to Advance Former’s Protein-Based Drug Program
  
• FDA Gives Roche’s Avastin the Go-Ahead for Metastatic Renal Carcinoma
  
• Novartis’ Afinitor Receives EU Sanction for Advanced RCC After Failed Anti-VEGF Therapy
  
• FDA Clears Sandoz’ Generic Competitor to Astellas Transplant Drug
  
• Oxford BioMedica and AGI Therapeutics Push On with Drugs That Failed Phase III Trials
  
• Japan Sanctions Three Novartis Drugs for Hypertension, Advanced Renal Cancer, and Type 2 Diabetes
  
• Astellas Bids $3.5B on OSI for Cancer Focus
  
• OSI Accepts Astellas' Increased $4B Cash Takeover Offer
  
• GSK Taps NCCN to Conduct Cancer Clinical Testing for $4M
  
• Astellas and Cardiome Halt Enrollment in Phase IIIb AF Trial Following Cardiogenic Shock
  
• Protein Sciences Expands Flu Vaccine Candidate License Arrangement with UMN
  
• Agensys Taps BioWa Technology for Cancer Antibody Discovery
  
• Astellas Buys Maxygen’s Stake in Protein Drug Firm for $76M
  
• Astellas to Submit Marketing Application for Overactive Bladder Therapy This Year Following Phase III Success
  
• Prometheus Pays Wilex $19M for U.S. Rights to Phase III Anticancer mAb
  
• Astellas Reports Positive Data from Phase III Trial with Overactive Bladder Drug
  
• Scientists Suggest a Molecular Pathway that May Identify RCC Patients Likely to Respond to Dasatinib
  
• Astellas Sells Prosidion Subsidiary’s DPP-IV Inhibitor Diabetes Assets to Royalty Pharma for $609M
  
• Astellas Ditches Development of Oral Direct Factor Xa Inhibitor Darexaban
  
• Agenus, NewVac Ink Cancer Vaccine Deal in Russia